Glaucoma Treatment Market to Grow from $7.2 Billion in 2025 to $10.8 Billion by 2035 Driven by Rising Prevalence and New Product Launches

Published: Jan 2026

Glaucoma treatment market was valued at $7.2 billion in 2025 and is projected to reach $10.8 billion by 2035, growing at a CAGR of 4.2% during the forecast period (2026-2035). The global glaucoma treatment market is witnessing strong momentum due to the increasing prevalence of glaucoma and the critical need for early intervention to prevent irreversible vision loss. As awareness of the disease grows, patients are seeking timely access to effective therapies, including prescription eye drops, oral medications, laser therapies, and surgical procedures. This demand is further reinforced by healthcare providers emphasizing proactive disease management and patients’ preference for minimally invasive options, boosting adoption across hospitals, retail pharmacies, and online channels. Recent FDA approvals and product launches have accelerated access to advanced therapies, enhancing treatment options for both open-angle and closed-angle glaucoma patients.

Browse the full report description of “Global Glaucoma Treatment Market Size, Share & Trends Analysis Report By Disease Indication (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, and Congenital Glaucoma), By Distribution Channel (Hospitals PHARMACY, RETAIL Pharmacy, and Online Pharmacy), By Drug Class (Prostaglandin Analogues, Alpha Agonist, Cholinergic, Beta Blockers, and Carbonic Anhydrase Inhibitors), Forecast Period 2026-2035.” Of https://www.omrglobal.com/industry-reports/glaucoma-treatment-market

Supporting this trend, glaucoma currently affects millions globally, with US patient numbers projected to rise from 5 million to 6.3 million by 2050. Traditional treatments such as prostaglandin analogues, beta blockers, alpha agonists, cholinergic agents, and carbonic anhydrase inhibitors remain central to therapy, helping reduce intraocular pressure and preserve vision. The increasing pipeline of FDA-approved drugs and new product launches is expanding therapeutic choices, improving patient adherence, and driving market growth across multiple distribution channels.

Market Coverage

  • The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
  • Segment Covered-
    • Drug Class
    • Disease Indication
    • Distribution Channel
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape – AbbVie Inc., Alcon AG, Bausch + Lomb Inc., Novartis AG, Pfizer Inc., among others.

Key questions addressed by the report.

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Glaucoma Treatment Market Report Segment

By Drug Class

  • Prostaglandin Analogues
  • Alpha Agonist
  • Cholinergic
  • Beta-Blockers
  • Carbonic Anhydrase Inhibitors

By Disease Indication

  • Closed Angle Glaucoma (CAG)
  • Open Angle Glaucoma (OAG)
  • Secondary Glaucoma
  • Congenital Glaucoma

By Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

 

Global Glaucoma Treatment Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/glaucoma-treatment-market